ArticleJournal of the National Cancer Institute2025
Risk of lymphoma among people with HIV in the United States, 2001-2019.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundLymphomas are among the most common malignancies in people with HIV. Although the widespread use of combination antiretroviral therapy has substantially reduced the risk of lymphoma among people with HIV, data on specific lymphoma subtypes remain limited and outdated.
methodsUsing data from the HIV/AIDS Cancer Match Study, a US cohort linking cancer and HIV registries and including 822 702 people with HIV, we assessed the relative risks of 14 lymphoma subtypes by calendar period and age group between 2001 and 2019. We estimated the risk of lymphoma subtypes using standardized incidence ratios (SIRs) adjusted for age, sex, race, ethnicity, and registry. Trends of standardized incidence ratios for lymphoma subtypes across calendar periods were estimated using Poisson regression overall and by age groups.
resultsThere were 6577 non-Hodgkin lymphoma (NHL) cases and 1783 Hodgkin lymphomas cases between 2001 and 2019. Standardized incidence ratios declined notably over time for most NHL subtypes, including diffuse large B-cell lymphoma, Burkitt lymphoma, peripheral T-cell lymphoma, central nervous system NHL, and follicular lymphoma. Between 2015 and 2019, lymphoma subtypes with elevated risk among people with HIV included diffuse large B-cell lymphoma (SIR = 5.38, 95% CI = 5.02 to 5.76), Burkitt lymphoma (SIR = 15.1, 95% CI = 12.6 to 17.9), peripheral T-cell lymphoma (SIR = 1.68, 95% CI = 1.26 to 2.20), central nervous system lymphoma (SIR = 8.85, 95% CI = 7.05 to 11.0), nodular sclerosis Hodgkin lymphoma (SIR = 4.04, 95% CI = 3.22 to 5.02), and other classic Hodgkin lymphoma (SIR = 8.99, 95% CI = 8.00 to 10.1). For most lymphoma subtypes, standardized incidence ratios for the 20- to 39-year-old-group were higher than for the 40- to 59-year-old and 60- to 84-year-old groups.
conclusionsThe risk of lymphomas among people with HIV in the United States declined between 2001 and 2019, with variations across histological subtypes and age groups. Despite overall declines, several NHL subtypes and Hodgkin lymphoma risk remained elevated, underscoring the continued lymphoma burden among people with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.